Consistently with REST being a novel EZH2-repressed target in NEPC, they have a significantly negative correlation of expression in two well-cited advanced prostate cancer datasets (Beltran_NatMed [39] in Fig. 5F and SU2C-PCF [52] in Supplementary Fig. S3C). Here, EZH2 is linked to prostate carcinoma.